refractory ocular inflammation VKH behcet'
Conditions
Interventions
refractory non infectious ocular Inflammation
Treatment
refractory ocular inflammation
Sponsors
Faculty of Medicine Siriraj Hospital Mahidol University
Eligibility
Sex/Gender
All
Age
10 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1) non-infectious eye inflammation which could not be controlled with prednisolone ≥ 10 mg/day combined with 2 immunosuppressive agents (refractory to treatment) or having adverse effects which required IMS cessation 2) patients agree to use GLM treatment (50 mg subcutaneous injection every 4 weeks) and are able to follow the treatment schedule
Exclusion criteria
Exclusion criteria: 1) patients affected with or suspected of infectious ocular inflammation 2) patients with active or history of tuberculosis 3) known allergy history of golimumab or related products 4) pregnant subjects
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| steroid dosage and number IMS agent before use golimumab 1 month, at every dose of golimumab until Aug 2019 dosage and number of agent,response to golimumab before use golimumab 1 month, at every dose of golimumab until Aug 2019 frequency of active inflammatory episodes before and after GLM treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| safety before use golimumab 1 month, at every dose of golimumab until Aug 2019 developed adverse events after GLM treatment | — |
Contacts
Public ContactNattaporn Tesavibul
Faculty of Medicine Siriraj Hospital, Mahidol University
Outcome results
None listed